# About Peptide Rejuvination — An Independent Skin & Aesthetics Research Desk > About Peptide Rejuvination: an independent literature digest on two Skin & Aesthetics research peptides, GLOW and Melanotan II. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice. A briskly clinical, citation-anchored review of the skin-remodeling and pigmentation-peptide literature. Not a vendor. Not a clinic. Not medical advice. ## What Peptide Rejuvination is Peptide Rejuvination is an independent editorial reference desk covering the published research on two peptides studied for aesthetic rejuvenation and pigmentation: GLOW, a multi-peptide skin- and tissue-repair blend, and Melanotan II, a melanocortin receptor agonist, with GLOW as the lead. The desk is organized like a clinical briefing, not a sales page: what a compound is, what the evidence actually shows, what to watch for, and what remains unknown. GLOW's page reads as three separate constituent literatures, because that is what the evidence is — no study has tested the blend as formulated. Melanotan II's page reads as a small, dated controlled-trial base set against a growing case-report record, because that is the honest state of its evidence too. Neither compound is an approved medicine. GLOW's constituents range from a legal cosmetic ingredient (topical GHK-Cu) to unapproved, WADA-prohibited research chemicals (BPC-157, TB-500). Melanotan II has never completed clinical development for any indication. The desk treats both with the same discipline: describe what was studied, in what model, and what was found — and say plainly where the evidence stops. ## How it is compiled Three principles govern this desk. First, every research claim is tied to a numbered citation — peer-reviewed journal articles and case reports, with DOIs and PubMed links, collected on the [references page](/references). Where a finding is a case report rather than a controlled trial, or an animal/cell model rather than human data, that distinction is stated, not implied away. Second, evidence is described at its actual strength. A single 10-person crossover trial from 1998 is reported as exactly that, not generalized into a blanket safety claim; a 2026 case report of self-administered dosing is reported as one documented instance, not a population-level frequency. Third, community-reported effects are kept structurally separate from cited findings. Where GLOW or Melanotan II users describe an effect in online write-ups, that material is labeled anecdotal on the page itself, and never presented as though it came from a controlled study. This separation is the single most important editorial rule on this desk, because it is the rule most often blurred by supplier marketing for both of these compounds. ## What it is not Peptide Rejuvination is not a pharmacy, a clinic, a supplier, or a broker for any peptide or research chemical. It does not sell, source, or recommend a vendor for GLOW, Melanotan II, or any of their constituents, and it has no referral or affiliate relationship with any supplier, clinic, or telehealth provider. It does not diagnose skin conditions, recommend cosmetic procedures, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person. Where a dose appears on this site, it is because a cited study or case report used that dose — never because this desk is suggesting it. Readers seeking dermatological or medical guidance should consult a licensed clinician in their own jurisdiction. Editorial correspondence on citation corrections, newly published studies, or out-of-date references can be directed to the [contact page](/contact); this desk monitors that correspondence but cannot respond to requests for medical advice. --- A clinician's-briefing digest of skin-remodeling and pigmentation research peptides — no products, no prescriptions, just the literature.